Clinical Trials Directory

Trials / Completed

CompletedNCT00082797

High-Dose Methotrexate and Leucovorin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

A Phase II Study Of Systemic High-Dose Methotrexate For The Treatment Of Glioblastoma Multiforme In Newly Diagnosed Patients With Measurable Disease

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
36 (estimated)
Sponsor
Eastern Cooperative Oncology Group · Network
Sex
All
Age
18 Years – 120 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Drugs used in chemotherapy, such as methotrexate, work in different ways to stop tumor cells from dividing so they stop growing or die. Leucovorin may decrease side effects caused by high-dose methotrexate. PURPOSE: This phase II trial is studying how well giving high-dose methotrexate together with leucovorin works in treating patients with newly diagnosed glioblastoma multiforme.

Detailed description

OBJECTIVES: Primary * Determine the response in patients with newly diagnosed glioblastoma multiforme treated with high-dose methotrexate and leucovorin calcium. Secondary * Determine the acute toxicity of this regimen in these patients. * Determine the duration of survival of patients treated with this regimen. OUTLINE: This is a multicenter study. Patients receive high-dose methotrexate IV over 4 hours on day 1 and oral or IV leucovorin calcium every 6 hours beginning on day 2 and continuing until blood methotrexate levels are acceptable. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive standard radiotherapy with or without chemotherapy. Patients with disease progression proceed to standard radiotherapy with or without chemotherapy upon stopping methotrexate therapy. Patients are followed at 30 days and then every 2 months for up to 2 years. PROJECTED ACCRUAL: A total of 19-36 patients will be accrued for this study.

Conditions

Interventions

TypeNameDescription
DRUGleucovorin calcium
DRUGmethotrexate

Timeline

Start date
2005-07-12
Primary completion
2007-05-01
First posted
2004-05-19
Last updated
2023-06-15

Locations

65 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00082797. Inclusion in this directory is not an endorsement.